Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
5.22
-0.03 (-0.57%)
At close: May 12, 2026, 4:00 PM EDT
6.06
+0.84 (16.09%)
After-hours: May 12, 2026, 7:59 PM EDT
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK’s WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
| Name | Position |
|---|---|
| Dr. Angelos M. Stergiou M.D., ScD h.c. | Founder, President, CEO & Director |
| Dr. Dragan Cicic M.D., MBA | Senior VP & Chief Development Officer |
| Mr. Andrew Elnatan | Senior VP of Regulatory Affairs, CMC & Quality |
| Mr. John Thomas Burns CPA | Senior VP & CFO |
| Ms. Stacy E. Yeung | VP, General Counsel & Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-04-23 | DEFA14A | tm261477d3_defa14a.htm |
| 2026-03-20 | S-3ASR | tm269045d1_s3asr.htm |
| 2026-03-19 | 8-K | sls-20260319.htm |
| 2026-03-19 | 10-K | sls-20251231.htm |
| 2026-03-11 | 8-K | tm268596d1_8k.htm |
| 2026-01-08 | 8-K | tm262494d1_8k.htm |
| 2025-11-21 | CORRESP | filename1.htm |
| 2025-11-12 | 10-Q | sls-20250930.htm |
| 2025-10-10 | S-3 | tm2528102d1_s3.htm |
| 2025-10-03 | 8-K | tm2527877d1_8k.htm |